JPRN-UMIN000012561已完成未知
Clinical outcome of pazopanib in Japanese patients with soft tissue sarcoma; Multicenter study - Clinical outcome of pazopanib in Japanese patients with soft tissue sarcoma;Multicenter study
Japanese Musculoskeletal Oncology Group0 个研究点目标入组 200 人开始时间: 2013年12月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who are not treated in the registered institutions of Japanese Musculoskeletal Oncology Group will be excluded from this study.
研究者
相似试验
进行中（未招募）
不适用
A study of the effectiveness and safety of the drug Pazopanib for use in patients with advanced kidney cancer who are suffering symptoms from their illness.MedDRA version: 14.1Level: LLTClassification code 10038416Term: Renal clear cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Clear cell renal cell carcinomaEUCTR2011-001211-31-GBniversity of Birmingham75
招募中
4 期
A Study to evaluate the effectiveness and safety of Pazopanib in a real world scenario in patients with advanced stage of renal cell carcinoma.CTRI/2017/04/008347ovartis Healthcare Pvt Ltd
已完成
2 期
Phase II Trial of Apixaban in Japanese Patients with Cancer-Associated Venous Thromboembolismcancer-associated venous thromboemborism (CA-VTE)JPRN-UMIN000028447Kobe University Hospital, Medical Oncology / Hematology62
已完成
3 期
A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma(JCOG1605, JCOG-PACS)Primary cutaneous angiosarcoma which has become refractory or there was intolerance to paclitaxelJPRN-UMIN000031438Japan Clinical Oncology Group (JCOG)30
招募中
1 期
A Study of Zanidatamab in Japanese Subjects With Locally Advanced or Metastatic HER2-Expressing Cancersocally advanced (unresectable) and/or metastatic HER2-expressing cancerJPRN-jRCT2031210161Rajen Oza48